Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 61.31 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 86.52 | Oscillator | Sell |
| Williams %R (14) | -8.47 | Oscillator | Sell |
| MACD (12, 26, 9) | 1.51 (Hist 0.66) | Oscillator | Strong Buy |
| Average Directional Index (14) | 22.45 (+DI 23.2 / -DI 14.1) | Trend | Buy |
Current price $95.91
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 12, 26 |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 15, 26 | Lofton Kevin E | director | J-Other | 182 | — |
FY2026 · 10-K disclosure
FY2026 · 10-K disclosure
| EMA 20 | 92.33 | MA | Strong Buy |
| SMA 20 | 90.74 | MA | Strong Buy |
| EMA 50 | 90.54 | MA | Strong Buy |
| SMA 50 | 91.38 | MA | Strong Buy |
| SMA 200 | 88.22 | MA | Strong Buy |
| BTIG |
| maintain |
| Buy |
| Buy |
| Sep 30, 26 | TD Cowen | maintain | Buy | Buy |
| Sep 3, 26 | UBS | maintain | Buy | Buy |
| Sep 2, 26 | RBC Capital | maintain | Outperform | Outperform |
| Sep 2, 26 | Baird | maintain | Neutral | Neutral |
| Sep 2, 26 | Stifel | maintain | Hold | Hold |
| Sep 2, 26 | B of A Securities | maintain | Buy | Buy |
| Sep 2, 26 | Truist Securities | maintain | Hold | Hold |
| Sep 2, 26 | Wells Fargo | maintain | Overweight | Overweight |
| Oct 15, 26 |
| Marinaro Michael |
| officer: EVP, Pres MedSurg and Americas |
| S-Sale |
| 10,420 @ $96.00 |
| $1.00M |
| Oct 15, 26 | Martha Geoffrey | director, officer: Chairman and CEO | S-Sale | 50,000 @ $95.00 | $4.75M |
| Sep 16, 26 | Kiil Harry Skip | officer: EVP & President Cardiovascular | S-Sale | 1,483 @ $93.65 | $138.9K |
| Sep 15, 26 | Blomquist Denise L. | officer: Chief Accounting Officer | G-Gift | 600 | — |
| Aug 20, 26 | Marinaro Michael | officer: EVP, Pres MedSurg and Americas | F-InKind | 1,084 @ $92.30 | $100.1K |
| Aug 3, 26 | Blomquist Denise L. | officer: Chief Accounting Officer | A-Award | 2,337 | — |
| Jul 31, 26 | Blomquist Denise L. | officer: Chief Accounting Officer | F-InKind | 212 @ $85.39 | $18.10K |
Stock news · updated daily
On October 22, 2026, Medtronic PLC (MDT) shares rose 3.8% to a current price of $96.59. This movement comes amid a 52-week range of $73.31 to $106.33, indicatin
NEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an R&D Day on November 12th, 2026, at 3:00pm ET in New York City.
Global APEX and REAL PULSE Registry analyses report strong safety and procedural outcomes across atrial and ventricular arrhythmias Medtronic continues to strengthen its position in cardiac ablation, building on a legacy of innovation in electrophysiology GALWAY, Ireland, Oct. 22, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive real-world registry results for the Affera™ Mapping and Ablation System with the Sphere-9™ Catheter and the PulseSelect™ Pulsed Field Ablation (PFA) System. The global registry analyses, presented at the Asia Pacific Heart Rhythm Society (APHRS) 2026 scientific meeting, evaluated prospectively enrolled patients with atrial fibrillation (AFib) and ventricular tachycardia (VT).
Arlington Financial Advisors LLC bought a new position in Medtronic PLC (NYSE: MDT) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm bought 9,743 shares of the medical technology company's stock, valued at approximately $841,000. Several other institutional investors and hedge funds have also made
In the latest trading session, Medtronic (MDT) closed at $92.77, marking a -2.09% move from the previous day.
Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to record highs.
First Bank and Trust lifted its stake in shares of Medtronic PLC (NYSE: MDT) by 43.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 35,848 shares of the medical technology company's stock after purchasing an additional 10,881 shares during the quarter.
Medtronic PLC (NYSE: MDT - Get Free Report) CEO Geoffrey Martha sold 50,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total value of $4,750,000.00. Following the completion of the transaction, the chief executive officer owned 277,866 shares in
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Sep 1, 2026 | 1.39 | 1.45 | Beat 4.3% | $9.76B |
| Jun 3, 2026 | 1.54 | 1.55 | Beat 0.6% | $9.81B |
| Feb 17, 2026 | 1.34 | 1.36 | Beat 1.5% | $9.02B |
| Nov 18, 2025 | 1.31 | 1.36 | Beat 3.8% | $8.96B |
| Aug 19, 2025 | 1.23 | 1.26 | Beat 2.4% | $8.58B |
| May 21, 2025 | 1.58 | 1.62 | Beat 2.5% | $8.93B |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Oct 21, 2026 | 2026-10-21 17:18:02 | View |
| 11-K | Oct 21, 2026 | 2026-10-21 16:13:29 | View |
| 11-K | Oct 21, 2026 | 2026-10-21 16:12:20 | View |
| 8-K | Oct 19, 2026 | 2026-10-19 16:23:27 | View |
| 4 | Oct 16, 2026 | 2026-10-16 18:02:07 | View |
| 4 | Oct 16, 2026 | 2026-10-16 18:00:50 | View |
| SC 13G/A | Oct 16, 2026 | 2026-10-16 16:21:24 | View |
| 4 | Oct 16, 2026 | 2026-10-16 16:18:01 | View |
| SC TO-I/A | Oct 14, 2026 | 2026-10-14 08:20:21 | View |
| 425 | Oct 14, 2026 | 2026-10-14 08:05:46 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | MDT | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 23.4x | 26.8x · sector 20.7x | In line |
| Forward P/E (FY27E) | 16.0x | EPS est. 5.98 | Discount |
| Price / Book | 2.4x | 2.3x | In line |
| Price / Sales | 3.3x | 3.5x | In line |
| EV / EBITDA | 14.7x | 15.7x | In line |
| Return on equity | 10.6% | — | Healthy |
| Gross margin | 66.7% | 65.9% | In line |
| Debt / Equity | 0.56 | 0.52 | Moderate |
| Piotroski / Altman Z | 9/9 | Z 3.00 | Safe zone |
Discounted cash flow model